RHOA and Hepatic fibrosis: In conclusion, these results suggest that FA combined with BMSC treatment can induce greater release of miR-19b-3p, which inhibits the activation of HSCs by suppressing the RhoA/ROCK1/SRF and RhoA/ROCK1/LIMK1 pathways, contributing to alleviation of liver fibrosis.